Tourmaline Bio's 15min chart shows KDJ Golden Cross, Bullish Marubozu signal.

Based on the 15-minute chart for Tourmaline Bio, there is evidence of a shift in momentum towards the upside, as indicated by the KDJ Golden Cross that occurred on September 19, 2025 at 12:00. This bullish signal is supported by the presence of a bullish Marubozu candlestick pattern, which suggests that buyers have taken control of the market and are likely to drive the stock price upwards. As a result, there is a strong potential for further price appreciation, and the bullish momentum is expected to continue.

Tourmaline Bio (NASDAQ: TRML) has been in the spotlight following Novartis' (NYSE: NVS) acquisition agreement, with mixed reactions from analysts and a potential bullish technical signal. BMO Capital downgraded the stock from Outperform to Market Perform, raising the price target to $48.00 from $35.00 BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news^[1]. The downgrade was attributed to the pending acquisition, with analysts expecting a smooth deal closure by the fourth quarter of 2025.

The acquisition, valued at approximately $1.4 billion, has seen several other analysts respond with downgrades. Jefferies downgraded Tourmaline Bio from Buy to Hold, adjusting the price target to $47.50. Guggenheim downgraded the stock from Buy to Neutral, describing the deal price as fair and indicative of the pharmaceutical industry's interest in IL-6 as a target. Wedbush followed suit, downgrading the stock from Outperform to Neutral with a price target of $48 BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news^[1].

Meanwhile, a shareholder alert has been issued, with the M&A Class Action Firm investigating the acquisition terms. The firm is investigating whether the deal is fair for Tourmaline shareholders, who will receive $48.00 in cash per share SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)^[2].

Technically, Tourmaline Bio's stock has shown signs of bullish momentum. A KDJ Golden Cross occurred on September 19, 2025, at 12:00, indicating a shift in momentum towards the upside. This bullish signal is supported by the presence of a bullish Marubozu candlestick pattern, suggesting that buyers have taken control of the market and are likely to drive the stock price upwards .

Despite the mixed analyst reactions and the pending acquisition, the bullish technical signals suggest a potential for further price appreciation. Investors should keep an eye on the acquisition's progress and the stock's technical indicators for further insights.